Gradient Investments LLC Purchases 50,650 Shares of Pfizer Inc. (NYSE:PFE)

Gradient Investments LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,160,482 shares of the biopharmaceutical company's stock after acquiring an additional 50,650 shares during the period. Gradient Investments LLC's holdings in Pfizer were worth $29,407,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of PFE. Tallon Kerry Patrick bought a new position in Pfizer during the 4th quarter valued at $509,000. Brighton Jones LLC increased its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $49,000. Finally, Concord Wealth Partners increased its position in shares of Pfizer by 253.0% during the 4th quarter. Concord Wealth Partners now owns 17,634 shares of the biopharmaceutical company's stock valued at $468,000 after purchasing an additional 12,638 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

PFE stock traded down $0.09 during mid-day trading on Tuesday, reaching $23.37. 35,434,503 shares of the company traded hands, compared to its average volume of 41,046,415. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $132.85 billion, a P/E ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a fifty day moving average price of $23.08 and a 200-day moving average price of $25.04.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.82 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.36%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PFE. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.